Literature DB >> 24569778

Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact.

A Tefferi1, T L Lasho1, C Finke1, A A Belachew1, E A Wassie1, R P Ketterling2, C A Hanson3, A Pardanani1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24569778     DOI： 10.1038/leu.2014.83

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  9 in total

1.  CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.

Authors:  A Tefferi; T L Lasho; C M Finke; R A Knudson; R Ketterling; C H Hanson; M Maffioli; D Caramazza; F Passamonti; A Pardanani
Journal:  Leukemia       Date:  2014-01-09       Impact factor: 11.528

2.  DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.

Authors:  Naseema Gangat; Domenica Caramazza; Rakhee Vaidya; Geeta George; Kebede Begna; Susan Schwager; Daniel Van Dyke; Curtis Hanson; Wenting Wu; Animesh Pardanani; Francisco Cervantes; Francesco Passamonti; Ayalew Tefferi
Journal:  J Clin Oncol       Date:  2010-12-13       Impact factor: 44.544

3.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

4.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.

Authors:  Francisco Cervantes; Brigitte Dupriez; Arturo Pereira; Francesco Passamonti; John T Reilly; Enrica Morra; Alessandro M Vannucchi; Ruben A Mesa; Jean-Loup Demory; Giovanni Barosi; Elisa Rumi; Ayalew Tefferi
Journal:  Blood       Date:  2008-11-06       Impact factor: 22.113

5.  Mutations and prognosis in primary myelofibrosis.

Authors:  A M Vannucchi; T L Lasho; P Guglielmelli; F Biamonte; A Pardanani; A Pereira; C Finke; J Score; N Gangat; C Mannarelli; R P Ketterling; G Rotunno; R A Knudson; M C Susini; R R Laborde; A Spolverini; A Pancrazzi; L Pieri; R Manfredini; E Tagliafico; R Zini; A Jones; K Zoi; A Reiter; A Duncombe; D Pietra; E Rumi; F Cervantes; G Barosi; M Cazzola; N C P Cross; A Tefferi
Journal:  Leukemia       Date:  2013-04-26       Impact factor: 11.528

Review 6.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

Authors:  James W Vardiman; Jüergen Thiele; Daniel A Arber; Richard D Brunning; Michael J Borowitz; Anna Porwit; Nancy Lee Harris; Michelle M Le Beau; Eva Hellström-Lindberg; Ayalew Tefferi; Clara D Bloomfield
Journal:  Blood       Date:  2009-04-08       Impact factor: 22.113

7.  Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.

Authors:  Giada Rotunno; Carmela Mannarelli; Paola Guglielmelli; Annalisa Pacilli; Alessandro Pancrazzi; Lisa Pieri; Tiziana Fanelli; Alberto Bosi; Alessandro M Vannucchi
Journal:  Blood       Date:  2013-12-26       Impact factor: 22.113

8.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

Authors:  J Nangalia; C E Massie; E J Baxter; F L Nice; G Gundem; D C Wedge; E Avezov; J Li; K Kollmann; D G Kent; A Aziz; A L Godfrey; J Hinton; I Martincorena; P Van Loo; A V Jones; P Guglielmelli; P Tarpey; H P Harding; J D Fitzpatrick; C T Goudie; C A Ortmann; S J Loughran; K Raine; D R Jones; A P Butler; J W Teague; S O'Meara; S McLaren; M Bianchi; Y Silber; D Dimitropoulou; D Bloxham; L Mudie; M Maddison; B Robinson; C Keohane; C Maclean; K Hill; K Orchard; S Tauro; M-Q Du; M Greaves; D Bowen; B J P Huntly; C N Harrison; N C P Cross; D Ron; A M Vannucchi; E Papaemmanuil; P J Campbell; A R Green
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

9.  JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.

Authors:  Elisa Rumi; Daniela Pietra; Virginia Ferretti; Thorsten Klampfl; Ashot S Harutyunyan; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Chiara Elena; Ilaria C Casetti; Chiara Milanesi; Emanuela Sant'antonio; Marta Bellini; Elena Fugazza; Maria C Renna; Emanuela Boveri; Cesare Astori; Cristiana Pascutto; Robert Kralovics; Mario Cazzola
Journal:  Blood       Date:  2013-12-23       Impact factor: 22.113
  9 in total
  49 in total

Review 1.  What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?

Authors:  Paola Guglielmelli; Giada Rotunno; Annalisa Pacilli; Alessandro Maria Vannucchi
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 2.  Clinical relevance between CALR mutation and myeloproliferative neoplasms.

Authors:  Zhiyuan Wu; Chen Zhang; Xiaochao Ma; Ming Guan
Journal:  Stem Cell Investig       Date:  2015-02-16

3.  JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms.

Authors:  Shuichi Shirane; Marito Araki; Soji Morishita; Yoko Edahiro; Hiraku Takei; Yongjin Yoo; Murim Choi; Yoshitaka Sunami; Yumi Hironaka; Masaaki Noguchi; Michiaki Koike; Naohiro Noda; Akimichi Ohsaka; Norio Komatsu
Journal:  Haematologica       Date:  2014-11-14       Impact factor: 9.941

4.  Constitutional genetic association with CALR mutations?

Authors:  L Eder-Azanza; P Evans; C Wickham; S Akiki; J L Vizmanos; A Chase; N C P Cross
Journal:  Leukemia       Date:  2015-07-22       Impact factor: 11.528

5.  p.Y317H is a new JAK2 gain-of-function mutation affecting the FERM domain in a myelofibrosis patient with CALR mutation.

Authors:  Laura Eder-Azanza; Cristina Hurtado; David Navarro-Herrera; Paula Aranaz; Francisco J Novo; José L Vizmanos
Journal:  Haematologica       Date:  2017-05-04       Impact factor: 9.941

6.  Rapid and sensitive detection of calreticulin type 1 and 2 mutations by real-time quantitative PCR.

Authors:  Michael Zinke; Vanasa Nageswaran; Richard Reinhardt; Thomas Burmeister
Journal:  Mol Diagn Ther       Date:  2015-10       Impact factor: 4.074

7.  The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants.

Authors:  Ayalew Tefferi; Terra L Lasho; Alexander Tischer; Emnet A Wassie; Christy M Finke; Alem A Belachew; Rhett P Ketterling; Curtis A Hanson; Animesh D Pardanani
Journal:  Blood       Date:  2014-10-09       Impact factor: 22.113

Review 8.  Prognosis of Primary Myelofibrosis in the Genomic Era.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-08

9.  Mutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanism.

Authors:  Michael R Garbati; Catherine A Welgan; Sally H Landefeld; Laura F Newell; Anupriya Agarwal; Jennifer B Dunlap; Tapan K Chourasia; Hyunjung Lee; Johannes Elferich; Elie Traer; Rogan Rattray; Michael J Cascio; Richard D Press; Grover C Bagby; Jeffrey W Tyner; Brian J Druker; Kim-Hien T Dao
Journal:  Am J Hematol       Date:  2016-02       Impact factor: 10.047

10.  Calreticulin mutations in Chinese with primary myelofibrosis.

Authors:  Bing Li; Junqing Xu; Jingya Wang; Robert Peter Gale; Zefeng Xu; Yajuan Cui; Lin Yang; Ruixian Xing; Xiaofei Ai; Tiejun Qin; Yue Zhang; Peihong Zhang; Zhijian Xiao
Journal:  Haematologica       Date:  2014-07-04       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.